TuisMOLN • SWX
add
Molecular Partners AG
Vorige sluiting
CHF 4,89
Dagwisseling
CHF 4,89 - CHF 4,99
Jaarwisseling
CHF 3,11 - CHF 9,50
Markkapitalisasie
200,20 m CHF
Gemiddelde volume
20,26 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
SWX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CHF) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 681,00 k | -73,20% |
Bedryfskoste | 4,41 m | -0,38% |
Netto inkomste | -16,40 m | -43,40% |
Netto winsgrens | -2,41 k | -435,08% |
Wins per aandeel | -0,49 | — |
EBITDA | -14,00 m | -8,64% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CHF) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 143,62 m | -30,49% |
Totale bates | 154,21 m | -29,30% |
Totale aanspreeklikheid | 15,43 m | -29,56% |
Totale ekwiteit | 138,78 m | — |
Uitstaande aandele | 33,19 m | — |
Prys om te bespreek | 1,17 | — |
Opbrengs op bates | -22,46% | — |
Opbrengs op kapitaal | -24,30% | — |
Kontantvloei
Netto kontantverandering
| (CHF) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -16,40 m | -43,40% |
Kontant van bedrywe | -13,28 m | -0,68% |
Kontant van beleggings | 14,22 m | -20,00% |
Kontant van finansiering | -301,00 k | -1,01% |
Netto kontantverandering | 66,00 k | -98,72% |
Beskikbare kontantvloei | -8,09 m | -4,19% |
Meer oor
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Gestig
2004
Webwerf
Werknemers
162
